Ivermectin for preventing and treating COVID-19
Is ivermectin effective for COVID ‐19? Updated Cochrane review'Ivermectin for preventing and treating COVID ‐19 'Key messagesWe found no evidence to support the use of ivermectin for treating COVID ‐19 or preventing SARS‐CoV‐2 infection. The evidence base improved slightly in this update, but is still limited.Evaluation of ivermectin is continuing in 31 ongoing trials, and we will update this review again when their results become available. What is ivermectin?Ivermectin is a medicine used to treat parasites, such as intestinal parasites in animals, and scabies in humans. It is inexpensive and is widely used in...
Source: Cochrane News and Events - June 21, 2022 Category: Information Technology Authors: Katie Abbotts Source Type: news
Latin Foods Market Issues Voluntary Nationwide Recall of Artri King Reforzado Con Ortiga Y Omega 3 Due to the Presence of Undeclared Diclofenac and Dexamethasone
Latin Foods Market is voluntarily recalling one lot, LOTE 334 21, of Artri King Reforzado con Ortiga y Omega 3 tablets to the consumer level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 15, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Baricitinib Has Better Safety Profile Than Dexamethasone When Added to Remdesivir for COVID-19 Baricitinib Has Better Safety Profile Than Dexamethasone When Added to Remdesivir for COVID-19
For patients with severe COVID-19 requiring supplemental oxygen, combining remdesivir with either baricitinib or dexamethasone led to similar survival rates off mechanical ventilation by day 29, but dexamethasone was associated with significantly more side effects, in the ACTT-4 randomized controlled trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 9, 2022 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Neodecadron (Neomycin and Dexamethasone) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 7, 2022 Category: Drugs & Pharmacology Source Type: news
Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial, The Lancet Respiratory Medicine
RCT (n=1,010) found a similar rate of mechanical ventilation free survival at day 29 for baricitinib vs dexamethasone (+remdesivir) for patients hospitalised with COVID-19 (87.0% vs 87.6%), though there were fewer adverse events with baricitinib (30% vs 37% of patients p=0.014). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 26, 2022 Category: Consumer Health News Source Type: news
Common Medications Can Prolong Back Pain, Study Says
A clinical trial will be needed to verify the research, which offered a warning about taking steroids or nonprescription drugs to soothe aches that many experience. (Source: NYT Health)
Source: NYT Health - May 15, 2022 Category: Consumer Health News Authors: Gina Kolata Tags: Back (Human Body Part) Pain Chronic Condition (Health) Drugs (Pharmaceuticals) Mice Steroids Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Ibuprofen (Drug) Dexamethasone (Drug) Research Science Translational Medicine (Journal) your-f Source Type: news
Common Medications Can Prolong Back Pain When Overused, Study Says
A clinical trial will be needed to verify the research, which offered a warning about taking steroids or nonprescription drugs for weeks on end. (Source: NYT Health)
Source: NYT Health - May 12, 2022 Category: Consumer Health News Authors: Gina Kolata Tags: Back (Human Body Part) Pain Chronic Condition (Health) Drugs (Pharmaceuticals) Mice Steroids Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Ibuprofen (Drug) Dexamethasone (Drug) Research Science Translational Medicine (Journal) your-f Source Type: news
Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma
(MedPage Today) -- Adding the monoclonal antibody elotuzumab (Empliciti) to lenalidomide (Revlimid) and dexamethasone failed to improve outcomes for patients with newly diagnosed, transplant-ineligible multiple myeloma, a phase III trial showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 12, 2022 Category: Hematology Source Type: news
Dexamethasone Reduces Morphine Consumption After Total Knee Arthroplasty
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - April 21, 2022 Category: Orthopaedics Tags: CME Article Source Type: news
Novel Steroid Therapy May Counter Ataxia Telangiectasia Novel Steroid Therapy May Counter Ataxia Telangiectasia
A novel therapy for ataxia telangiectasia that delivers dexamethasone sodium phosphate through red blood cells is both ' promising and impressive ' in a new phase 3 trial, experts say.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 8, 2022 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first ...
Source: Johnson and Johnson - March 30, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
